|
Post by golfeveryday on Feb 12, 2017 8:31:09 GMT -5
lakon.. why are you ruling out 180 ext... Mnkd will get the extension in my opinion. They have to get the RS approval first so there is corrective action available to the company during the next 180 days if necessary.
|
|
|
Post by falconquest on Feb 12, 2017 9:47:11 GMT -5
Hi Falcon, not sure about quad by June. But we have a protracted state of flat scripts and increasingly obvious thesis that the market first just wants to see material upticks in scripts, coverage and yes any reasonable acceptance of Afrezza. For those close to detail we see a buildup of sales activity that may have a reasonable hit rate that could double or triple scripts in a relatively short time. This could cause the market to react and trigger a reasonably material run. This then followed by more success and subsequent runs. Run by run and soon we're talking about real gains. Optimistic Saturday check-in. Hey bioexec, I do agree that a turn around in script count could have a springboard affect on the share price. I think it would take not only a healthy turn around but one that is sustained as well. The problem here is that Afrezza has not proven itself from a sales standpoint. It hasn't even really gotten started. Unfortunately the problem is, despite all current efforts.....it hasn't really gotten started. That's the concern! I'm still in the "show me" camp. Show me that this is a viable, marketable product and then I'll believe. I spent well over 10 years believing and I ran out of belief. BTW, I did quite well this past week. ;-) Oh, and for those that want to jump on my "viable" comment I am referring to sales not efficacy.
|
|
|
Post by falconquest on Feb 12, 2017 9:58:20 GMT -5
And I keep hearing unrealistic positive crap as though all of a sudden things are going to magically turn around because Matt has a plan that he is concealing in his back pocket. That is not only unfair and misleading to others but establishes unrealistic expectations for Matt. Don't misinterpret me, I believe there are many positive things taking place, and I also believe we have the greatest insulin product ever developed. What I would like to hear are logical comments about investment strategy with a potential delisting staring us in the face. I'll stop. Good luck with the pie in the sky solutions. And I keep hearing unrealistic positive crap as though all of a sudden things are going to magically turn around because Matt has a plan that he is concealing in his back pocket. Only you, yourself, are letting those positive speculations which you refer to as crap affect you in such a dramatic way. Why does it bother you so much? You do not have to read them, or even post a response because when you do, you persist to keep going on and on. It bothers you that there are many people that enjoy sharing positive speculations. That is not only unfair and misleading to others What others? Adults that are intelligent enough to be able to use a computer and even know how to invest? Eh, I don't think so. Speculation is speculation and if someone's mind can be influenced by an internet poster that is sharing their speculative thoughts then I fear that those same people probably are influenced in far, far more dramatic ways in everyday life. God forbid if they were to ever watch an infomercial or commercial. So—how do you rationale what you claim? Who are these "others" and how have they been affected by an internet post that is about speculation? but establishes unrealistic expectations for Matt. So you also are claiming that Matt feels he must live up to speculation or wild theories? How do you know this? Did he actually tell you this because I know for a fact he did not. That is just you making a wild nonsensical claim, which you are trying to paint in as a fact. Don't misinterpret me, I am not. You are straightforward. I believe there are many positive things taking place, and I also believe we have the greatest insulin product ever developed. Right. What I would like to hear are logical comments about investment strategy with a potential delisting staring us in the face. Before, you wanted logical explanations for why anyone should even still hold MNKD. Now, you want investment advice from people on the internet. You already know what choices are available. Stop playing games. Tell me this, what is more unfair and misleading in your opinion—someone trying to get others to share investment advice posted on here for all to see (this is a public forum btw) or wild speculation and theories for all to see? I sure hope you get where I am going with this. Hypocrite. I'll stop. Good luck with the pie in the sky solutions.Good luck to you as well. I'll make this easy for you Mango. $19.00 to $0.52. In another thread I wrote "I would like to hear a plausible case made for continuing to hold Mannkind shares" and I received only one viable response. What is yours? I have moved on from Mannkind and am trying to make the long trek back to recovering my losses. I did quite well this past week. How does your investment look? I will not post any more on this thread because the last one was locked and I do not want that for everyone again.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 12, 2017 10:52:05 GMT -5
NRx, TRx and cash are the only numbers that are important right now. We have around 80 reps that hit the streets this Monday morning. Some were selling Afrezza as Touchpoint employees so they know the product, docs and diabetes. They need no time to ramp. The other reps likely came from Sanofi, Novo or another diabetes company. They know the docs, diabetes and have just completed what I assume to be a very thorough education on Afrezza. Within three weeks, my expectation is that reps will start to have a positive impact on NRx. Modest at the beginning but should have stable growth that ramps W/W. Two potential / significant impacts of a 180 day extension: 1 - extra 6 mos to sell Afrezza and if the growth is solid and steady and refill rate is vastly improved over what the Sanofi and Touchpoint sales teams were able to accomplish - SP should grow. Given better sample and titration packs, Mannkind Cares prior auth program, improved insurance coverage and the Spirometry issue managed in a more effective manner the inertia to get an Afrezza prescription written and filled is less that it was even 6 months ago not to mention a year or when Sanofi began selling. Still a pretty small salesforce but as I have said several times, a few hundred endos giving Afrezza support would ramp sales nicely. 2 - a potential deal or two that brings in > $50mm + so that even if Afrezza sales don't drive SP > $1, we have enough cash so that even with a RS, there is not an immediate need to raise more money. Food for thought: lets say sales start to grow and we get some type of extension and by late May, Mannkind is trading at $1.85 / share, what as CEO or CFO would you do? With the burn rate around $10mm / month, unless you knew definitively that a lot of cash was coming in due to a deal, you would likely want to raise enough money for another 6 months. Of the 700 million shares authorized, about 500 million are issued. Would Matt simply start to trickle around 30 mm shares into the market and take in around $54 mm? Once word hit the street, SP would drop again. Would Matt try to privately place the shares (can he do this and then issue a PR and would going this route require dangling some warrants so additional dilution?). Another option, if things are going well, would Matt still consider a RS to reduce the share count? Matt has to have some investment bankers to advise on some of this stuff. Al Mann had a strong relationship with BOA. Perhaps Matt still speaks / works with them. You really believe this could nearly quadruple in price by June? No idea where SP will be by June. My final paragraph was more of a strategic finance question to look at the pros and cons of doing a RS or not in an environment where Mannkind is seeing some sales traction. RS in general are not good but if the company was starting to show a stable decent growth trajectory, would there be benefit of doing a RS and then raising $$ vs selling more authorized but not outstanding shares into the market. Not sure what your background is - mine is not finance or capital markets so that is why I ask. As it sits now, a RS is a certainty unless some type of significant event in the next week or so. Once the RS takes place, issue becomes whether or not Afrezza sales grow quick enough and how adverse is the dilution with additional capital raised via common equity. After RS if money comes in from a deal or two, we have the impact of RS but not further dilution at least for the time being. If Afrezza sales don't pick up in the next few months, these discussions will become meaningless. The next few months to me will be to prove proof of concept. A salesforce of 80 isn't enough to get us to the promise land but if it gets reasonable traction in proportion to salesforce size and burn rate, then Matt P and Mike C can make a case that commercialization of Afrezza is viable and scalable for the US and likely EX-US.
|
|
|
Post by mango on Feb 12, 2017 23:41:36 GMT -5
And I keep hearing unrealistic positive crap as though all of a sudden things are going to magically turn around because Matt has a plan that he is concealing in his back pocket. Only you, yourself, are letting those positive speculations which you refer to as crap affect you in such a dramatic way. Why does it bother you so much? You do not have to read them, or even post a response because when you do, you persist to keep going on and on. It bothers you that there are many people that enjoy sharing positive speculations. That is not only unfair and misleading to others What others? Adults that are intelligent enough to be able to use a computer and even know how to invest? Eh, I don't think so. Speculation is speculation and if someone's mind can be influenced by an internet poster that is sharing their speculative thoughts then I fear that those same people probably are influenced in far, far more dramatic ways in everyday life. God forbid if they were to ever watch an infomercial or commercial. So—how do you rationale what you claim? Who are these "others" and how have they been affected by an internet post that is about speculation? but establishes unrealistic expectations for Matt. So you also are claiming that Matt feels he must live up to speculation or wild theories? How do you know this? Did he actually tell you this because I know for a fact he did not. That is just you making a wild nonsensical claim, which you are trying to paint in as a fact. Don't misinterpret me, I am not. You are straightforward. I believe there are many positive things taking place, and I also believe we have the greatest insulin product ever developed. Right. What I would like to hear are logical comments about investment strategy with a potential delisting staring us in the face. Before, you wanted logical explanations for why anyone should even still hold MNKD. Now, you want investment advice from people on the internet. You already know what choices are available. Stop playing games. Tell me this, what is more unfair and misleading in your opinion—someone trying to get others to share investment advice posted on here for all to see (this is a public forum btw) or wild speculation and theories for all to see? I sure hope you get where I am going with this. Hypocrite. I'll stop. Good luck with the pie in the sky solutions.Good luck to you as well. I'll make this easy for you Mango. $19.00 to $0.52. In another thread I wrote "I would like to hear a plausible case made for continuing to hold Mannkind shares" and I received only one viable response. What is yours? I have moved on from Mannkind and am trying to make the long trek back to recovering my losses. I did quite well this past week. How does your investment look? I will not post any more on this thread because the last one was locked and I do not want that for everyone again. Viable response: I don't have one. This is the only stock I have ever invested in and I know nothing about the stock market. I don't care about trying to influence you. The reason why I will never sell is because I want to support something that inspired me. How does my investment look: Average is $1.04
|
|
|
Post by rockstarrick on Feb 13, 2017 2:06:07 GMT -5
lakon.. why are you ruling out 180 ext... Mnkd will get the extension in my opinion. They have to get the RS approval first so there is corrective action available to the company during the next 180 days if necessary. I believe once the reverse split is approved by shareholders the extension is automatic, I think I read something about this a while back when AVXL split. Anyhow, if this is true, the AMF or whoever is controlling Als 153 million shares would probably approve the split and the extension would be granted. Ill look for the link to make sure.
|
|
|
Post by promann on Feb 13, 2017 2:39:31 GMT -5
Mnkd will get the extension in my opinion. They have to get the RS approval first so there is corrective action available to the company during the next 180 days if necessary. I believe once the reverse split is approved by shareholders the extension is automatic, I think I read something about this a while back when AVXL split. Anyhow, if this is true, the AMF or whoever is controlling Als 153 million shares would probably approve the split and the extension would be granted. Ill look for the link to make sure. You bring up a good point. I would be interested in seeing that link once you find it.. I'm hoping the request for a approval will read if it becomes nessacary to do a reverse split we would like the share holders approval to do so. that way no one can bitch if the reverse split does not proceed.
|
|
|
Post by rockstarrick on Feb 13, 2017 2:51:09 GMT -5
Mnkd will get the extension in my opinion. They have to get the RS approval first so there is corrective action available to the company during the next 180 days if necessary. I believe once the reverse split is approved by shareholders the extension is automatic, I think I read something about this a while back when AVXL split. Anyhow, if this is true, the AMF or whoever is controlling Als 153 million shares would probably approve the split and the extension would be granted. Ill look for the link to make sure. Here's what I found, Nasdaq Deficiency Notice Stocks listed on the Nasdaq that fail to file quarterly, annual or other SEC-mandated reports by the due date may receive a notice of intention to delist. Another major trigger for delisting is the failure of the stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days. Both scenarios will result in the issuance of a deficiency notice to the company. Initial Grace Period The Nasdaq does not immediately delist a company for noncompliance. It provides the company with a grace period in which to "cure" -- or eliminate -- the deficiency. The grace period lasts for 180 calendar days after receipt of the deficiency notice. The company's securities remain listed during this time. Second Grace Period Optional The Nasdaq may grant a 180-day extension of the initial grace period. In such a case, the stock remains listed throughout the the extension. Not all companies qualify for this second grace period. The market value of publicly held shares of a company's stock must be at least $1 million. The market value is calculated by multiplying the publicly held shares -- the total number of shares outstanding minus any shares held by officers, directors, employee stock ownership plans or beneficial owners of 10 percent or more -- by the closing bid price. These companies must have maintained the other non-price listing requirements. Conditions for Second Grace Period Granting of the second extension is not automatic for those that meet the requirements. A noncompliant company must inform the Nasdaq in writing of its intent to cure the deficiency and how it will do so. Companies often announce their intention to perform a reverse stock split in order to return the share price to above $1. A 1-for-2 reverse stock split provides investors with half the number of shares at twice the price. If the Nasdaq believes the company can cure the deficiency during the extension period, it will grant the additional time. Appeals and Delisting If a company fails to notify the Nasdaq of its intent to correct the deficiency -- or if the exchange does not believe the company can correct it -- the Nasdaq will deny the extension. The company can appeal a negative decision to the Nasdaq's internal hearing panel. An appeal results in a stay of the listing until the process concludes. If a company opts not to appeal or loses the appeal, the Nasdaq will remove the security from trading and finalize the delisting. Sponsored links
|
|
|
Post by falconquest on Feb 13, 2017 5:06:01 GMT -5
I believe once the reverse split is approved by shareholders the extension is automatic, I think I read something about this a while back when AVXL split. Anyhow, if this is true, the AMF or whoever is controlling Als 153 million shares would probably approve the split and the extension would be granted. Ill look for the link to make sure. Here's what I found, Nasdaq Deficiency Notice Stocks listed on the Nasdaq that fail to file quarterly, annual or other SEC-mandated reports by the due date may receive a notice of intention to delist. Another major trigger for delisting is the failure of the stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days. Both scenarios will result in the issuance of a deficiency notice to the company. Initial Grace Period The Nasdaq does not immediately delist a company for noncompliance. It provides the company with a grace period in which to "cure" -- or eliminate -- the deficiency. The grace period lasts for 180 calendar days after receipt of the deficiency notice. The company's securities remain listed during this time. Second Grace Period Optional The Nasdaq may grant a 180-day extension of the initial grace period. In such a case, the stock remains listed throughout the the extension. Not all companies qualify for this second grace period. The market value of publicly held shares of a company's stock must be at least $1 million. The market value is calculated by multiplying the publicly held shares -- the total number of shares outstanding minus any shares held by officers, directors, employee stock ownership plans or beneficial owners of 10 percent or more -- by the closing bid price. These companies must have maintained the other non-price listing requirements. Conditions for Second Grace Period Granting of the second extension is not automatic for those that meet the requirements. A noncompliant company must inform the Nasdaq in writing of its intent to cure the deficiency and how it will do so. Companies often announce their intention to perform a reverse stock split in order to return the share price to above $1. A 1-for-2 reverse stock split provides investors with half the number of shares at twice the price. If the Nasdaq believes the company can cure the deficiency during the extension period, it will grant the additional time. Appeals and Delisting If a company fails to notify the Nasdaq of its intent to correct the deficiency -- or if the exchange does not believe the company can correct it -- the Nasdaq will deny the extension. The company can appeal a negative decision to the Nasdaq's internal hearing panel. An appeal results in a stay of the listing until the process concludes. If a company opts not to appeal or loses the appeal, the Nasdaq will remove the security from trading and finalize the delisting. Sponsored links Understand that AVXL did a reverse to allow the company to become listed on the Nasdaq exchange from the OTC. They did not split due to potential de-listing. I recommend diligence on this stock.
|
|
|
Post by promann on Feb 13, 2017 5:12:52 GMT -5
I believe once the reverse split is approved by shareholders the extension is automatic, I think I read something about this a while back when AVXL split. Anyhow, if this is true, the AMF or whoever is controlling Als 153 million shares would probably approve the split and the extension would be granted. Ill look for the link to make sure. Here's what I found, Nasdaq Deficiency Notice Stocks listed on the Nasdaq that fail to file quarterly, annual or other SEC-mandated reports by the due date may receive a notice of intention to delist. Another major trigger for delisting is the failure of the stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days. Both scenarios will result in the issuance of a deficiency notice to the company. Initial Grace Period The Nasdaq does not immediately delist a company for noncompliance. It provides the company with a grace period in which to "cure" -- or eliminate -- the deficiency. The grace period lasts for 180 calendar days after receipt of the deficiency notice. The company's securities remain listed during this time. Second Grace Period Optional The Nasdaq may grant a 180-day extension of the initial grace period. In such a case, the stock remains listed throughout the the extension. Not all companies qualify for this second grace period. The market value of publicly held shares of a company's stock must be at least $1 million. The market value is calculated by multiplying the publicly held shares -- the total number of shares outstanding minus any shares held by officers, directors, employee stock ownership plans or beneficial owners of 10 percent or more -- by the closing bid price. These companies must have maintained the other non-price listing requirements. Conditions for Second Grace Period Granting of the second extension is not automatic for those that meet the requirements. A noncompliant company must inform the Nasdaq in writing of its intent to cure the deficiency and how it will do so. Companies often announce their intention to perform a reverse stock split in order to return the share price to above $1. A 1-for-2 reverse stock split provides investors with half the number of shares at twice the price. If the Nasdaq believes the company can cure the deficiency during the extension period, it will grant the additional time. Appeals and Delisting If a company fails to notify the Nasdaq of its intent to correct the deficiency -- or if the exchange does not believe the company can correct it -- the Nasdaq will deny the extension. The company can appeal a negative decision to the Nasdaq's internal hearing panel. An appeal results in a stay of the listing until the process concludes. If a company opts not to appeal or loses the appeal, the Nasdaq will remove the security from trading and finalize the delisting. Sponsored links Thanks Rick I've read this before. The conditions for the 2nd grace period says it all. MannKind does not have to do a reverse split unless they are still under a buck during the end of the 2nd 180 day grace period. That's how I and others read that.. And is why they need the approval for the reverse split to show they can cure the deficiency if need be.
|
|
|
Post by golfeveryday on Feb 13, 2017 7:14:44 GMT -5
Here's what I found, Nasdaq Deficiency Notice Stocks listed on the Nasdaq that fail to file quarterly, annual or other SEC-mandated reports by the due date may receive a notice of intention to delist. Another major trigger for delisting is the failure of the stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days. Both scenarios will result in the issuance of a deficiency notice to the company. Initial Grace Period The Nasdaq does not immediately delist a company for noncompliance. It provides the company with a grace period in which to "cure" -- or eliminate -- the deficiency. The grace period lasts for 180 calendar days after receipt of the deficiency notice. The company's securities remain listed during this time. Second Grace Period Optional The Nasdaq may grant a 180-day extension of the initial grace period. In such a case, the stock remains listed throughout the the extension. Not all companies qualify for this second grace period. The market value of publicly held shares of a company's stock must be at least $1 million. The market value is calculated by multiplying the publicly held shares -- the total number of shares outstanding minus any shares held by officers, directors, employee stock ownership plans or beneficial owners of 10 percent or more -- by the closing bid price. These companies must have maintained the other non-price listing requirements. Conditions for Second Grace Period Granting of the second extension is not automatic for those that meet the requirements. A noncompliant company must inform the Nasdaq in writing of its intent to cure the deficiency and how it will do so. Companies often announce their intention to perform a reverse stock split in order to return the share price to above $1. A 1-for-2 reverse stock split provides investors with half the number of shares at twice the price. If the Nasdaq believes the company can cure the deficiency during the extension period, it will grant the additional time. Appeals and Delisting If a company fails to notify the Nasdaq of its intent to correct the deficiency -- or if the exchange does not believe the company can correct it -- the Nasdaq will deny the extension. The company can appeal a negative decision to the Nasdaq's internal hearing panel. An appeal results in a stay of the listing until the process concludes. If a company opts not to appeal or loses the appeal, the Nasdaq will remove the security from trading and finalize the delisting. Sponsored links Thanks Rick I've read this before. The conditions for the 2nd grace period says it all. MannKind does not have to do a reverse split unless they are still under a buck during the end of the 2nd 180 day grace period. That's how I and others read that.. And is why they need the approval for the reverse split to show they can cure the deficiency if need be. I believe that is correct.
|
|
|
Post by saxcmann on Feb 13, 2017 9:09:12 GMT -5
Thanks Rick I've read this before. The conditions for the 2nd grace period says it all. MannKind does not have to do a reverse split unless they are still under a buck during the end of the 2nd 180 day grace period. That's how I and others read that.. And is why they need the approval for the reverse split to show they can cure the deficiency if need be. I believe that is correct. I believe that's correct also but cash will be a problem in 6 months so they will split and dilute unless they get cash, imo.
|
|
|
Post by mnkdnewb on Feb 13, 2017 9:20:54 GMT -5
I believe that is correct. I believe that's correct also but cash will be a problem in 6 months so they will split and dilute unless they get cash, imo. The way I read the statement that was put out today is that as soon as it has been approved the r/s will be implemented the same day. This is not an approval for a possible r/s, it is approval for a r/S and the r/s is happening. Share holders are not voting on the ratio either - it is up to the board. The vote will happen, it will be approved and on March 2 there will be significantly fewer shares at a higher pps. To think this won't happen is borderline foolish
|
|
|
Post by saxcmann on Feb 13, 2017 9:30:50 GMT -5
I believe that's correct also but cash will be a problem in 6 months so they will split and dilute unless they get cash, imo. The way I read the statement that was put out today is that as soon as it has been approved the r/s will be implemented the same day. This is not an approval for a possible r/s, it is approval for a r/S and the r/s is happening. Share holders are not voting on the ratio either - it is up to the board. The vote will happen, it will be approved and on March 2 there will be significantly fewer shares at a higher pps. To think this won't happen is borderline foolish Likely YES RS happens after vote approved. Likely dilution next...
|
|
|
Post by rockstarrick on Feb 13, 2017 10:03:54 GMT -5
Here's what I found, Nasdaq Deficiency Notice Stocks listed on the Nasdaq that fail to file quarterly, annual or other SEC-mandated reports by the due date may receive a notice of intention to delist. Another major trigger for delisting is the failure of the stock to maintain a minimum closing bid price of $1 for 30 consecutive trading days. Both scenarios will result in the issuance of a deficiency notice to the company. Initial Grace Period The Nasdaq does not immediately delist a company for noncompliance. It provides the company with a grace period in which to "cure" -- or eliminate -- the deficiency. The grace period lasts for 180 calendar days after receipt of the deficiency notice. The company's securities remain listed during this time. Second Grace Period Optional The Nasdaq may grant a 180-day extension of the initial grace period. In such a case, the stock remains listed throughout the the extension. Not all companies qualify for this second grace period. The market value of publicly held shares of a company's stock must be at least $1 million. The market value is calculated by multiplying the publicly held shares -- the total number of shares outstanding minus any shares held by officers, directors, employee stock ownership plans or beneficial owners of 10 percent or more -- by the closing bid price. These companies must have maintained the other non-price listing requirements. Conditions for Second Grace Period Granting of the second extension is not automatic for those that meet the requirements. A noncompliant company must inform the Nasdaq in writing of its intent to cure the deficiency and how it will do so. Companies often announce their intention to perform a reverse stock split in order to return the share price to above $1. A 1-for-2 reverse stock split provides investors with half the number of shares at twice the price. If the Nasdaq believes the company can cure the deficiency during the extension period, it will grant the additional time. Appeals and Delisting If a company fails to notify the Nasdaq of its intent to correct the deficiency -- or if the exchange does not believe the company can correct it -- the Nasdaq will deny the extension. The company can appeal a negative decision to the Nasdaq's internal hearing panel. An appeal results in a stay of the listing until the process concludes. If a company opts not to appeal or loses the appeal, the Nasdaq will remove the security from trading and finalize the delisting. Sponsored links Understand that AVXL did a reverse to allow the company to become listed on the Nasdaq exchange from the OTC. They did not split due to potential de-listing. I recommend diligence on this stock. Yes, do your own dd, I didn't mean to make it look like AVXL split to avoid delisting, that just happened to be when I came across this article while searching why a company would implement a reverse split. Thanks falcon for pointing this out
|
|